Nortis’ versatile microfluidic technology enables researchers to engineer a wide range of three-dimensional tissue microenvironments.
About the size of a credit card, Nortis’ unique microfluidic chips can be used to grow tissue microenvironments by seeding cells into tubular voids within extracellular matrix gels. The chip design offers the flexibility to generate a variety of tissue architectures based on cell types and matrix materials selected.
Small, portable perfusion platforms house the disposable chips and supporting media and collection reservoirs. Three-shelved docking stations that reside in a standard tissue culture incubator increase experimental throughput and flexibility by enabling up to twelve independent experiments to be run at a time. Perfusion through both the tissue lumen and surrounding extralumenal space allow physico-chemical gradients to be created and perfusion fluids and cells to be collected for downstream analysis. Each docking station shelf can easily be removed and the small perfusion platform/chip assemblies accommodate easy transport between the cell culture incubator, laminar flow hood, and microscope stage.
A key element of Nortis’ technology is the ability to subject the tissues to fluid flow directly through the vessel lumen, which enables:
Nortis provides an efficient, affordable alternative to animal testing that can accelerate research and advance scientific exploration. By supporting fluid flow, 3D tissue culture, and robust analysis in one scalable, user-friendly platform, Nortis offers a flexible approach to drive human health research and drug development.
Small, disposable chips and perfusion hardware enable creation of various human tissue microenvironments for relevant insight into the world’s most challenging biological questions. These tools are designed to serve a variety of applications, including:
Engineer, perfuse, and observe living human microvasculature
Reproduce functional units of specific organs
The technology represents an important alternative to lab animals in pharmaceutical drug development, where more predictive preclinical test models are urgently needed to increase clinical trial success. This advance will overcome a large barrier to developing therapeutic drugs and vaccines for diseases like cancer, diabetes, Alzheimer’s disease, infectious diseases, cardiovascular disease, and stroke.
Nortis is collaborating with multiple investigators throughout the United States to prepare its core technology for commercial launch in early 2015.
Nortis is dedicated to developing a new generation of in vitro systems that advance the discovery of novel therapies and reduce the timeline and costs associated with their translation into the clinic.
Come visit the Nortis booth at the Life Science Innovation Northwest on June 30 – July 1st in Seattle, WA, and listen to a presentation by our CEO, Thomas Neumann, to learn more about our company and upcoming commercial product.
Come visit the Nortis booth at the World Pharma Congress on June 10 – 12th in Boston, MA, and learn more about our upcoming commercial product.
Read about how the University of Pittsburgh and the University of Washington are developing organs-on-a-chip using the Nortis technology in Discover magazine’s latest edition.
Nortis headquarters has officially moved to a new location in Eastlake! Our manufacturing facility is located across the lake in Woodinville, WA.
1616 Eastlake Ave E, Suite 270
Seattle, WA 98102, USA
17280 Woodinville-Redmond Rd NE/Suite B828
Woodinville, WA 98072, USA